ZURA

Business Context and Reporting Period

Zura Bio Limited (ZURA) is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. The company is an emerging growth company and smaller reporting company. This summary covers the quarterly period ended June 30, 2025 (2025 Q2).

Key pipeline assets include tibulizumab (ZB-106), currently in Phase 2 trials for hidradenitis suppurativa (HS) and systemic sclerosis (SSc); crebankitug (ZB-168); and torudokimab (ZB-880). The company has no approved products and has not generated revenue from product sales.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 54% ($6.3 million) for the three months ended June 30, 2025, compared to the same period in 2024. This was driven by a 57% increase in R&D expenses and a 50% increase in G&A expenses.
• R&D Drivers: The increase in R&D expenses was primarily due to costs associated with advancing Phase 2 clinical trials for tibulizumab in HS and SSc, including increased CRO fees and personnel costs.
• Net Loss: Net loss attributable to Class A Ordinary Shareholders increased by 26% to $16.0 million for the quarter, compared to $12.7 million in the prior year quarter. For the six-month period, the net loss increased by 150% to $33.4 million, largely due to the absence of a $7.0 million non-cash adjustment to redeemable noncontrolling interest that reduced the reported loss in the prior year.
• Interest Income: Interest income decreased by 22% to $1.7 million for the quarter, attributed to lower interest rates on cash balances compared to the prior year.

Guidance, Outlook, Risks, and Unusual Items

• Liquidity Outlook: Management believes existing cash and cash equivalents ($154.5 million) are sufficient to fund operations through 2027. The company expects to continue incurring significant losses and will require additional capital to fund clinical development and commercialization.
• ATM Program: The company sold 3.0 million shares under its At-The-Market (ATM) program in Q1 2025 for net proceeds of $5.1 million. No sales occurred in Q2 2025. Approximately $114.0 million remains available under the sales agreement.
• Internal Review and Contingencies: The company is conducting an internal review by an Audit Subcommittee regarding agreements with BAFFX17 and Stone Peach.
  • BAFFX17: A $5.0 million milestone payment invoice was received on June 30, 2025. Payment is pending the outcome of the review.
  • Stone Peach: Requests were received in July 2025 to exercise a Put Option (for $5.0 million) and a Put Right (for 2.0 million shares) regarding Z33 Series Seed Preferred Shares. These have not been effected pending the review.
• Risk Factors: Significant risks include the failure of clinical trials, inability to obtain regulatory approval, dependence on third-party manufacturers (including WuXi Biologics in China), and potential impacts of international trade policies and tariffs on supply chains.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $154.5 million cash balance against projected burn rates, considering the potential need for additional financing before 2027.
• Contingent Liabilities: Monitor the outcome of the Audit Subcommittee's review regarding the $5.0 million BAFFX17 payment and the Stone Peach Put Option/Right exercises, which could impact cash or share count.
• Clinical Milestones: Track progress and data readouts for the TibuSHIELD (HS) and TibuSURE (SSc) Phase 2 trials, with topline data expected in late 2026.
• Share Dilution: Review the impact of outstanding pre-funded warrants (30.4 million) and options (16.9 million) on future dilution.
• Regulatory Environment: Assess potential impacts of FDA/EMA disruptions and new U.S. trade tariffs on manufacturing costs and timelines.